Search Result

Results for "

Peptidic

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adenylate Cyclase (1) Aminopeptidase (2) Angiotensin Receptor (1) Antibiotic (2) Apelin Receptor (APJ) (1) Apoptosis (3) Arrestin (2) Bacterial (1) Bcl-2 Family (3) Beta-secretase (1) Biochemical Assay Reagents (1) CCR (1) Complement System (4) CRFR (1) CXCR (2) Cyclophilin (1) ERK (1) HCV (1) HIV Protease (1) MMP (5) Neurokinin Receptor (2) Neuropeptide B/W Receptor (1) Neurotensin Receptor (1) Opioid Receptor (2) Peptide-Drug Conjugates (PDCs) (1) PI3K (3) Potassium Channel (1) SARS-CoV (5) TGF-beta/Smad (3) Virus Protease (2)
By Research Areas:	Cancer (13) Cardiovascular Disease (5) Endocrinology (2) Infection (7) Inflammation/Immunology (9) Metabolic Disease (5) Neurological Disease (10)

By Targets:

Adenylate Cyclase (1)

Aminopeptidase (2)

Angiotensin Receptor (1)

Antibiotic (2)

Apelin Receptor (APJ) (1)

Apoptosis (3)

Arrestin (2)

Bacterial (1)

Bcl-2 Family (3)

Beta-secretase (1)

Biochemical Assay Reagents (1)

CCR (1)

Complement System (4)

CRFR (1)

CXCR (2)

Cyclophilin (1)

ERK (1)

HCV (1)

HIV Protease (1)

MMP (5)

Neurokinin Receptor (2)

Neuropeptide B/W Receptor (1)

Neurotensin Receptor (1)

Opioid Receptor (2)

Peptide-Drug Conjugates (PDCs) (1)

PI3K (3)

Potassium Channel (1)

SARS-CoV (5)

TGF-beta/Smad (3)

Virus Protease (2)

By Research Areas:

Cancer (13)

Cardiovascular Disease (5)

Endocrinology (2)

Infection (7)

Inflammation/Immunology (9)

Metabolic Disease (5)

Neurological Disease (10)

Inhibitors & Agonists

Fluorescent Dye

Peptides

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-106178

PMX-53 4 Publications Verification 3D53	Complement System	Cardiovascular Disease Inflammation/Immunology Cancer
PMX-53 (3D53) is a synthetic peptidic and a potent and orally active complement C5a receptor (CD88) antagonist with an IC₅₀ of 20 nM. PMX-53 is also a low-affinity MrgX2 agonist that stimulates MrgX2-mediated mast cell degranulation. PMX-53 specifically binds to C5aR1 and does not bind to the second C5aR (C5L2) and C3aR. PMX-53 has anti-inflammatory, anticancer and antiatherosclerotic effects .

HY-N6689

Destruxin A 1 Publications Verification	Antibiotic	Infection Cancer
Destruxin A (DA) is a cyclo-peptidic mycotoxin from the entomopathogenic fungus Metarhizium anisopliae, with insecticidal, anti-viral and antiproliferative activities .

HY-160239

HFI-437	Aminopeptidase	Neurological Disease
HFI-437 is a potent non-peptidic insulin-regulated aminopeptidase (IRAP) inhibitor with a K_i of 20 nM. HFI-437 is a cognitive enhancer .

HY-A0279A

Pristinamycin IA 1 Publications Verification Mikamycin B; Mikamycin IA	Bacterial Antibiotic	Infection
Pristinamycin IA (Mikamycin B) is a cycle-peptidic macrolactone antibiotic. Pristinamycin IA is a substrate of P-glycoprotein and inhibits its function. Pristinamycin IA is active against StaphyloEoccus and Srreptococcus .

HY-143216

Ensitrelvir 5+ Cited Publications S-217622	SARS-CoV Virus Protease	Infection
Ensitrelvir (S-217622) is the first orally active non-covalent, non-peptidic, SARS-CoV-2 3CL protease inhibitor (IC₅₀=13 nM) .

HY-168378

D-Val-Leu-Lys-pNA	Biochemical Assay Reagents	Others
D-Val-Leu-Lys-pNA (S-2251) is widely used as a plasmin specific peptidic substrate in biochemical studies .

HY-U00188

A81988 Abbott81988	Angiotensin Receptor	Cardiovascular Disease Endocrinology
A81988 is a potent, competitive, non-peptidic antagonist of angiotensin AT₁ receptors.

HY-101580

Paliroden SR 57667	Others	Neurological Disease
Paliroden is an orally bioactive neurotrophic, non-peptidic compound that activates synthesis of endogenous neurotrophines, used for treatment of Alzheimer's Disease and Parkinson's.

HY-151197

HIV protease-IN-1	HIV Protease	Infection
HIV protease-IN-1 (compound 1·succinate) is a potent HIV protease non-peptidic inhibitor, can be used to research AIDS .

HY-123270

RP23618	CCR	Infection Inflammation/Immunology
RP23618 is a non peptidic RANTES antagonist with the IC₅₀ of 3 μM. RP23618 inhibit RANTES-induced chemotaxis of THP-1 cells .

HY-143216A

Ensitrelvir fumarate 5+ Cited Publications S-217622 fumarate	SARS-CoV Virus Protease	Infection
Ensitrelvir (S-217622) fumarate is the first orally active non-covalent, non-peptidic, SARS-CoV-2 3CL protease inhibitor (IC₅₀=13 nM) .

HY-137322

THX-B	Neurotensin Receptor	Neurological Disease Metabolic Disease
THX-B is a potent and non-peptidic p75 ^NTR (neurotrophin receptor p75) antagonist. THX-B can be used in the research of diabetic kidney disease, neurodegenerative and inflammatory disorders .

HY-18006

NKP608 1 Publications Verification	Neurokinin Receptor	Neurological Disease Endocrinology
NKP608 is a non-peptidic derivative of 4-aminopiperidine which acts as a selective, specific and potent antagonist at the neurokinin-1 (NK-1) receptor both in vitro(IC50=2.6 nM) and in vivo.

HY-18694

CGS 27023A	MMP	Inflammation/Immunology
CGS 27023A is a non-peptidic and orally active MMP inhibitor with the K_i values of 43, 33, 20 and 8 nM for MMP-3, MMP-1, MMP-2 amd MMP-9, respectively. CGS 27023A can be used for study of arthritis .

HY-100866B

F1324 acetate	Bcl-2 Family	Cancer
F1324 acetate is a potent, high affinity peptidic inhibitor of B cell lymphoma 6 (BCL6), with an IC₅₀ of 1 nM. F1324 acetate exhibits binding t_1/2 value of 441 s and has strong inhibition activity against BCL6 PPI .

HY-100866

F1324	Bcl-2 Family	Cancer
F1324 is a potent, high affinity peptidic inhibitor of B cell lymphoma 6 (BCL6) with an IC₅₀ of 1 nM. F1324 exhibits binding t_1/2 value of 441 s and has strong inhibition activity against BCL6 PPI .

HY-P1107A

Antisauvagine-30 TFA aSvg-30 TFA	CRFR	Neurological Disease
Antisauvagine-30 TFA (aSvg-30 TFA) is a potent, highly selective and competitive CRF₂ receptor peptidic antagonist. Antisauvagine-30 TFA exhibits a K_d of 1.4 nM and 150 nM for mCRFR2β and CRFR1, respectively .

HY-108624

CYM 50769	Neuropeptide B/W Receptor	Cardiovascular Disease Inflammation/Immunology
CYM 50769 is a non-peptidic selective antagonist of neuropeptides B and W receptor 1 (NPBWR1). CYM 50769 can attenuates the NPW-23-induced cell proliferation in ATDC5. CYM 50769 can be used for researching endochondral bone formation .

HY-P0118

Disitertide P144	TGF-beta/Smad PI3K Apoptosis	Cancer
Disitertide (P144) is a peptidic transforming growth factor-beta 1 (TGF-β1) inhibitor specifically designed to block the interaction with its receptor. Disitertide (P144) is also a PI3K inhibitor and an apoptosis inducer .

HY-100866A

F1324 TFA	Bcl-2 Family	Cancer
F1324 TFA is a potent, high affinity peptidic inhibitor of B cell lymphoma 6 (BCL6), with an IC₅₀ of 1 nM. F1324 TFA exhibits binding t_1/2 value of 441 s and has strong inhibition activity against BCL6 PPI .

HY-P0118A

Disitertide TFA P144 TFA	TGF-beta/Smad PI3K Apoptosis	Cancer
Disitertide (P144) TFA is a peptidic transforming growth factor-beta 1 (TGF-β1) inhibitor specifically designed to block the interaction with its receptor. Disitertide TFA is also a PI3K inhibitor and an apoptosis inducer .

HY-P0118B

Disitertide diammonium Maximum Cited Publications 13 Publications Verification P144 diammonium	TGF-beta/Smad PI3K Apoptosis	Cancer
Disitertide (P144) diammonium is a peptidic transforming growth factor-beta 1 (TGF-β1) inhibitor specifically designed to block the interaction with its receptor. Disitertide diammonium is also a PI3K inhibitor and an apoptosis inducer .

HY-P1717

AMY-101 Cp40	Complement System SARS-CoV	Inflammation/Immunology
AMY-101 (Cp40), a peptidic inhibitor of the central complement component C3 (K_D = 0.5 nM), inhibits naturally occurring periodontitis in non-human primates (NHPs). AMY-101 (Cp40) exhibits a favorable anti-inflammatory activity in models with COVID-19 severe pneumonia with systemic hyper inflammation .

HY-P1717B

AMY-101 acetate 2 Publications Verification Cp40 acetate	Complement System SARS-CoV	Inflammation/Immunology
AMY-101 acetate (Cp40 acetate), a peptidic inhibitor of the central complement component C3 (K_D = 0.5 nM), inhibits naturally occurring periodontitis in non-human primates (NHPs). AMY-101 acetate (Cp40 acetate) exhibits a favorable anti-inflammatory activity in models with COVID-19 severe pneumonia with systemic hyper inflammation .

HY-108579

UCL 1684 dibromide	Potassium Channel	Cardiovascular Disease
UCL 1684 (dibromide) is a first nanomolar, non-peptidic small conductance calcium-activated potassium (SK) channel blocker. UCL 1684 (dibromide) is effective in preventing the development of atrial fibrillation due to potent atrial-selective inhibition of I_Na. UCL 1684 (dibromide) causes atrial-selective prolongation of ERP secondary to induction of postrepolarization refractoriness .

HY-P1717A

AMY-101 TFA 2 Publications Verification Cp40 TFA	Complement System SARS-CoV	Inflammation/Immunology
AMY-101 TFA (Cp40 TFA), a peptidic inhibitor of the central complement component C3 (K_D = 0.5 nM), inhibits naturally occurring periodontitis in non-human primates (NHPs). AMY-101 (Cp40) exhibits a favorable anti-inflammatory activity in models with COVID-19 severe pneumonia with systemic hyper inflammation .

HY-33009

AS057278	Others	Neurological Disease
AS057278 is a potent, selective, orally active and blood-brain barrier (BBB) penetrant non-peptidic D-amino acid oxidase (DAAO) inhibitor with an IC₅₀ value of 0.91 μM and EC₅₀ of 2.2-3.95 μM. AS057278 can normalize phencyclidine (PCP)-induced prepulse inhibition in mice. AS057278 can be used for researching schizophrenia .

HY-P10759

DTS-201 sodium	Peptide-Drug Conjugates (PDCs) Aminopeptidase	Cancer
DTS-201 sodium (CPI-0004Na) is a peptidic prodrug of Doxorubicin (HY-15142A). DTS-201, comprising the tetrapeptide portion, is cleaved by endopeptidases in the tumor environment to produce metabolites that subsequently enter the cell and are converted to active Doxorubicin. DTS-201 shows antitumoral efficacy in tumor xenograft models of prostate, breast, and lung cancer .

HY-12168

Tanomastat BAY 12-9566	MMP	Cancer
Tanomastat (BAY 12-9566) is an orally bioavailable, non-peptidic biphenyl matrix metalloproteinases (MMPs) inhibitor with a Zn-binding carboxyl group. The K_i values are 11, 143, 301, and 1470 nM for MMP-2, MMP-3, MMP-9, MMP-13 respectively. Tanomastat shows anti-invasive and antimetastatic activity in several experimental tumor models .

HY-133036

APJ receptor agonist 1	Apelin Receptor (APJ)	Cardiovascular Disease
APJ receptor agonist 1, a biphenyl acid derivative, is a potent APJ receptor (APJ-R) agonist (EC₅₀s 0.093 and 0.12 nM for human and rat APJ-R, respectively). APJ receptor agonist 1 displays in vitro potency to apelin-13, the endogenous peptidic ligand for the APJ receptor. APJ receptor agonist 1 has the potential for the research of heart failure .

HY-10472

LY2811376 10+ Cited Publications	Beta-secretase	Neurological Disease
LY2811376 is the first orally available non-peptidic β-secretase (BACE1) inhibitor with IC₅₀ of 239 nM-249 nM, that acts to decrease Aβ secretion with EC₅₀ of 300 nM, and demonstrates to have 10-fold selectivity towards BACE1 over BACE2, and more than 50-fold inhibition over other aspartic proteases including cathepsin D, pepsin, or renin.

HY-106982

Ezlopitant CJ-11,974	Neurokinin Receptor	Neurological Disease Metabolic Disease
Ezlopitant (CJ-11,974) is a selective, non-peptidic neurokinin-1 (NK-1)-receptor antagonist. Ezlopitant inhibits both acute and delayed emetic reactions induced by Cisplatin (HY-17394) in ferrets via acting on NK1 receptors in the central nervous system. Ezlopitant has the potential for pain, chemotherapy-induced emesis and irritable bowel syndrome research .

HY-130176

UFP-512	Opioid Receptor ERK Adenylate Cyclase	Neurological Disease
UFP-512 is a selective and potent σ-opioid receptor (DOP receptor) peptidic agonist with antidepressant- and anxiolytic-like effects. UFP-512 exhibits as a potent agonist on adenylyl cyclase inhibition and Erk1/2 activation. UFP-512 induces phosphorylation of DOP receptors on Ser ³⁶³ with a low desensitization of the cAMP pathway. UFP-512 is promising for research of mood disorders .

HY-P1682

Balixafortide POL6326	CXCR Arrestin	Cancer
Balixafortide (POL6326) is a potent, selective, well-tolerated peptidic CXCR4 antagonist with an IC₅₀ < 10 nM. Balixafortide shows 1000-fold selective for CXCR4 than a large panel of receptors including CXCR7. Balixafortide blocks β-arrestin recruitment and calcium flux with IC₅₀s < 10 nM. Balixafortide is also a potent hematopoietic stem and progenitor cell (HSPC) mobilizing agent. Anti-cancer effects .

HY-12168B

(Rac)-Tanomastat (Rac)-BAY 12-9566	MMP	Cancer
(Rac)-Tanomastat ((Rac)-BAY 12-9566) is the racemate of Tanomastat. Tanomastat (BAY 12-9566) is an orally bioavailable, non-peptidic biphenyl matrix metalloproteinases (MMPs) inhibitor with a Zn-binding carboxyl group. The K_i values are 11, 143, 301, and 1470 nM for MMP-2, MMP-3, MMP-9, MMP-13 respectively. Tanomastat shows anti-invasive and antimetastatic activity in several experimental tumor models .

HY-P1682A

Balixafortide TFA 1 Publications Verification POL6326 TFA	CXCR Arrestin	Cancer
Balixafortide TFA (POL6326 TFA) is a potent, selective, well-tolerated peptidic CXCR4 antagonist with an IC₅₀ < 10 nM. Balixafortide TFA shows 1000-fold selective for CXCR4 than a large panel of receptors including CXCR7. Balixafortide TFA blocks β-arrestin recruitment and calcium flux with IC₅₀s < 10 nM. Balixafortide TFA is also a potent hematopoietic stem and progenitor cell (HSPC) mobilizing agent. Anti-cancer effects .

HY-114091

PF-00356231 hydrochloride 1 Publications Verification	MMP	Inflammation/Immunology
PF-00356231 hydrochloride is a specific, non-peptidic, non-zinc chelating ligand and inhibitor of matrix metalloproteinase MMP-12 (IC₅₀=1.4 μM). PF-00356231 hydrochloride binds to MMP-12 and forms PF-00356231/MMP-12 complex. PF-00356231 hydrochloride shows potency against MMP-13, MMP-8, MMP-9, MMP-3 with IC₅₀s of 0.00065, 1.7, 0.98, 0.39 μM, respectively .

HY-125182

SMCypI C31	Cyclophilin HCV	Infection
SMCypI C31 is a non-peptidic cyclophilin inhibitor with potent peptidyl-prolyl cis/trans isomerases (PPIase) inhibitory activity (IC₅₀ of 0.1 µM). SMCypI C31 shows pangenotype anti-HCV activity with EC₅₀s ranging from 1.20 to 7.76 μM for genotype 1a, 1b, 2a, 3a, and 5a HCV subgenomic replicons (HCV-SGRs) and chimeric genotype 2a/4a HCV-SGRs. SMCypI C31 disrupts the cyclophilin A-NS5A interaction .

HY-114091A

PF-00356231	MMP	Inflammation/Immunology
PF-00356231 hydrochloride is a specific, non-peptidic, non-zinc chelating ligand and inhibitor of matrix metalloproteinase MMP-12 (IC₅₀=1.4 μM). PF-00356231 hydrochloride binds to MMP-12 and forms PF-00356231/MMP-12 complex. PF-00356231 hydrochloride shows potency against MMP-13, MMP-8, MMP-9, MMP-3 with IC₅₀s of 0.00065, 1.7, 0.98, 0.39 μM, respectively .

HY-101317A

TAN-67 SB-205607	Opioid Receptor	Metabolic Disease
TAN-67 (SB-205607) is a non-peptidic delta-opioid receptor agonist that exhibits significant antinociceptive activity in both diabetic and non-diabetic mice. TAN-67 demonstrates a marked and dose-dependent reduction in acetic acid-induced abdominal constrictions, with a notably stronger effect in diabetic mice compared to their non-diabetic counterparts. TAN-67's antinociceptive properties are primarily mediated through the activation of delta 1-opioid receptors, as indicated by the pronounced antagonism observed upon administration of a selective delta 1-opioid receptor antagonist.

Cat. No.	Product Name	Type

HY-W338079

Ac-Asp-Glu-Val-Asp-pNA	Fluorescent Dyes/Probes
Ac-Asp-Glu-Val-Asp-pNA is a peptidic substrate of caspase-3/7 .

Cat. No.	Product Name	Target	Research Area